Virtual Medical Centre Inc (fka VMCT)

[canon]

CEO of VMCT is scheduled to be interviewed Sunday October 24th at 8:00pm EST on http://www.blogtalkradio.com/ceocentral

Shares outstanding:
84,253,764
Float
12,782,000


Virtual Medical Centre Inc. (VMC) www.virtualmedicalcentre.com is a leader in online medical information and content for doctors, patients and consumers in Australasia and Asia. Recently listed (JUNE 2010) on the US OTCQB/PINKS & pending on the OTCBB: symbol VMCT, the company has initiated a strategy to expand globally & accelerate asset & earnings growth by executing a strategy that includes:

• Acquiring a controlling interest in Pharmacy Online (POL), an industry leader in the Australian online e-pharmacy market for prescription fulfillment and Over The Counter (OTC) product sales; a binding agreement has been signed. Upon closing revenue is projected to increase from $1,200,000 to $10, 000,000 in 6 months and $22,000,000 within 18 months

• Identifying additional synergistic acquisition targets where VMC’s online audience of 650,000 + monthly visitors can have an immediate impact on earnings; a non-binding agreement has been signed with a potential target

• Expansion of VMC’s content licensing platform outside of Australia. Currently VMC sells medical content to Telstra, Australia’s largest telecom company, and is in talks with entities in the UK, Singapore, NZ & North America

• Aggressively expand Visum, VMC’s paid for market research doctor forum service launched earlier this year. The market is large and relatively open. Sermo in the US exceeded $100, million in earnings selling its doctor forum services

• Partnering and expanding its online continuing medical education (CME) service; VMC is a leader in Australia and a MOU has been signed with a leading US CME provider and consultancy

• Partner to build, license and deploy VMC North America. Several potential partners have been identified

• Expanding its online advertising reach. Current clients include blue chip multi-national pharmaceutical companies such as Pfizer, Janssen-Cilag (a J&J company), Roche, Nycomed, Novartis, Eli Lilly and more

The opportunity is large, diverse and timely; the strategy well thought out and complimentary to the company’s core assets – medical and healthcare information and content. The POL acquisition strategy compliments and provides significant sales channels for the company’s user base of more than 650,000 monthly visitors. More than 10,000 medical specialists are registered with the site and the opportunity to increase this number will grow dramatically as the company expands to international markets setting a solid growth platform for the company’s Visum paid for market research service.

The company is already implementing and executing its growth plans on a number of fronts, Visum, CME and North American development. Expectations, integration and optimization of the POL acquisition will happen quickly and the company expects to realize the economic benefits within 6 months. Currently POL exceeds $7,000,000 in annual revenue with an online client base of approximately 170,000.

Key difference is quality and approach. WebMD and others in the space lean towards either a tabloid approach or a clinical approach to providing content. VMC takes a clinical AND doctor patient approach.

How can they do this?

VMC vet’s its material and content using the services of over 1100 medical specialists that review, write, and manage the quality control of the more than 40,000 pages of medical information, videos, surveys, reviews, forums and content that is updated every 12 hours. This allows us to provide medical content written by doctors for doctors AND provide medical, healthcare and patient content written by doctors for consumers and patients. This translates into more than 4.5 million page views per month.